Acute effects of the imidacloprid metabolite desnitro-imidacloprid on human nACh receptors relevant for neuronal signaling

Dominik Loser1,2 · Karin Grillberger3 · Maria G. Hinojosa4 · Jonathan Blum2 · Yves Haufe5 · Timm Danker1 · Ylva Johansson4 · Clemens Möller6 · Annette Nicke5 · Susanne H. Bennekou7 · Iain Gardner8 · Caroline Bauch9 · Paul Walker9 · Anna Forsby4 · Gerhard F. Ecker3 · Udo Kraushaar1 · Marcel Leist2

Received: 8 June 2021 / Accepted: 20 September 2021 / Published online: 10 October 2021 © The Author(s) 2021

Abstract

Several neonicotinoids have recently been shown to activate the nicotinic acetylcholine receptor (nAChR) on human neurons. Moreover, imidacloprid (IMI) and other members of this pesticide family form a set of diverse metabolites within crops. Among these, desnitro-imidacloprid (DN-IMI) is of special toxicological interest, as there is evidence (i) for human dietary exposure to this metabolite, (ii) and that DN-IMI is a strong trigger of mammalian nicotinic responses. We set out here to quantify responses of human nAChRs to DN-IMI and an alternative metabolite, IMI-olefin. To evaluate toxicological hazards, these data were then compared to those of IMI and nicotine. Ca2+-imaging experiments on human neurons showed that DN-IMI exhibits an agonistic effect on nAChRs at sub-micromolar concentrations (equipotent with nicotine) while IMI-olefin activated the receptors less potently (in a similar range as IMI). Direct experimental data on the interaction with defined receptor subtypes were obtained by heterologous expression of various human nAChR subtypes in Xenopus laevis oocytes and measurement of the transmembrane currents evoked by exposure to putative ligands. DN-IMI acted on the physiologically important human nAChR subtypes α7, α3β4, and α4β2 (high-sensitivity variant) with similar potency as nicotine. IMI and IMI-olefin were confirmed as nAChR agonists, although with 2–3 orders of magnitude lower potency. Molecular docking studies, using receptor models for the α7 and α4β2 nAChR subtypes supported an activity of DN-IMI similar to that of nicotine. In summary, these data suggest that DN-IMI functionally affects human neurons similar to the well-established neurotoxicant nicotine by triggering α7 and several non-α7 nAChRs.

Keywords

Live-cell calcium imaging · Pesticide metabolism · Nicotine · Developmental neurotoxicity · Molecular docking · Oocyte recording
The toxicological assessment of many pesticides is complicated by the fact that there is not only exposure to the original substances, but also to their many metabolites formed in the environment. This also applies to the neonicotinoids, a class of insecticides with long persistence within crops (Simon-Delso et al. 2015; Craddock et al. 2019; Thompson et al. 2020). They comprise, e.g., imidacloprid (IMI), acetamiprid, clothianidin, and thiacloprid. With a global market turnover of > 1 billion € (Jeschke et al. 2011; Sparks and Casida 2006). Besides cytochrome P450 enzymes, especially aldehyde oxidase seems to play an important role in this biotransformation (Schulz-Jander and Casida 2002; Schulz-Jander et al. 2002; Dick et al. 2005; Swenson and Casida 2013; Simon-Delso et al. 2015; Vardavas et al. 2018).

Imidacloprid-olefin (IMI-olefin) has been detected in honey (Codling et al. 2016; Thompson et al. 2020), and DN-IMI is a major IMI degradation product in the environment (Anon 2006; Koshlukova 2006). The latter metabolite is produced abiotically by photodegradation (17% of all IMI), but also biotically as the dominant bacterial metabolite, and as a major metabolite in many plants (Anon 2006; Koshlukova 2006). It has, e.g., been found in drinking water (Klarich et al. 2017; Craddock et al. 2019; Thompson et al. 2020) and it has been reported to be formed in diverse foods such as apples, tomatoes, eggplants, and potatoes, where it accounted for around 10–30% of IMI degradation products. It reached concentrations in the 10–30 µg/kg range in apples and potatoes and up to 300 µg/kg in fodder corn (Anon 2006). The outdoor use of IMI has been banned in Europe in 2018 (European Commission 2018), due to unacceptable toxicity risks for bees (European Food Safety Authority [EFSA] 2016), and in 2020 the approval of IMI expired (European Commission 2020). However, exposure via the diet still occurs via imported food...
commodities, and until now, several EU countries still grant temporary exemptions and notify the EU of these emergency authorizations (https://ec.europa.eu/food/plant/pesticides/ eu-pesticides-database/ppp/pppeas/screen/home). The current dietary risk assessment on IMI in Europe covers the exposure to the parent compound IMI and its metabolites. However, there is no specific residue definition for DN-IMI (European Food Safety Authority [EFSA] et al. 2019). This means that it is assumed that the toxicological potency is similar to the parent compound.

DN-IMI has also been detected in mice exposed to IMI. This suggests that it can also be produced within mammals by endogenous metabolism (Ford and Casida 2006; Swenson and Casida 2013). This is consistent with findings of DN-IMI and IMI-olefin in human urine samples analyzed in a recent biomonitoring study (Wang et al. 2020).

The previous knowledge of IMI metabolism shows that a shift in the bioactivity spectrum can occur. For instance, the metabolite DN-IMI has a strongly reduced potency on insect nAChRs, but in turn an increased affinity for mammalian nAChRs (Liu et al. 1993; Chao and Casida 1997; Tomizawa et al. 2000). This is in line with studies in mice that suggested a higher toxicity of DN-IMI, compared to its parent compound IMI (Chao and Casida 1997; Tomizawa et al. 2000). Furthermore, binding assays using mammalian nAChRs have shown that DN-IMI has an affinity similar to the high-affinity ligand nicotine (Tomizawa and Casida 1999; D’Amour and Casida 1999; Tomizawa et al. 2000). Nicotine is a well-known neurotoxicant and developmental neurotoxicant for vertebrates, including man (Levin et al. 1993; Slikker Jr et al. 2005; LeSage et al. 2006; Grandjean and Landrigan 2006; Dwyer et al. 2009; Slotkin et al. 2016; Zahedi et al. 2019). Therefore, IMI metabolites mimicking the activity profile of nicotine on human receptors are of high toxicological concern.

The activation of ionotropic receptors like nAChRs on neurons leads to a depolarization of the cell membrane, and thereby, activates voltage-dependent Ca2+ channels. The transient influx of Ca2+ into the cell increases the intracellular free Ca2+ concentration ([Ca2+]i), which can be measured by Ca2+-imaging in neuronal cell cultures (Leist and Nicotera 1998; Sirekono et al. 2019; Grunwald et al. 2019; Loser et al. 2021b). This method is based on the quantifications of fluorescence signals of calcium-sensitive dyes introduced into the cells, and it is amenable to high-throughput formats (Sirekono et al. 2019; Karreman et al. 2020; Brüll et al. 2020; Loser et al. 2021b). Alternatively, xenobiotic effects on individual nAChR subtypes may be measured directly by the recording of the transmembrane currents in Xenopus laevis oocytes, and we developed a molecular docking approach explaining these findings. To gather background information on the persistence and distribution of DN-IMI in man, a toxicokinetic model was implemented and parameterized by metabolism data from human hepatocytes. The broad data set of this study was used for a preliminary risk assessment of DN-IMI.

Materials and methods

Materials and chemicals

An overview of experimental tool compounds and toxicants is given in Table S1. Consumables are indicated in the specific methods paragraphs. Chemical structures of
imidacloprid (IMI) (https://pubchem.ncbi.nlm.nih.gov/compound/86287518#section=2D-Structure), desnitro-imidacloprid (DN-IMI) (https://pubchem.ncbi.nlm.nih.gov/compound/10130527#section=2D-Structure) and imidacloprid-olefin (IMI-olefin) (https://pubchem.ncbi.nlm.nih.gov/compound/14626249#section=2D-Structure) were obtained from PubChem and visualized in ChemDraw JS (version 19.0.0-CDJS-19.0.x.9 + da9bec968, PerkinElmer).

LUHMES cell culture

The cultivation of the LUHMES cells was performed as described earlier (Scholz et al. 2011; Krug et al. 2013; Schildknecht et al. 2013). In brief, LUHMES cells were cultured in standard cell culture flasks (Sarstedt) that were pre-coated with 50 µg/ml poly-l-ornithine (PLO) and 1 µg/ml fibronectin (Sigma Aldrich) in H2O overnight at 37 °C. The cells were maintained in proliferation medium containing advanced DMEM/F12 (Gibco) with 2 mM L-glutamine, 1 × N2-supplement (Gibco), and 40 ng/ml recombinant human basic fibroblast growth factor (FGF-2, R&D Systems). The cells were kept at 37 °C and 5% CO2 and passaged three times a week when the culture reached a confluency of 75–90%. Cells were used until passage 18. For differentiation, cells were cultured in differentiation medium consisting of advanced DMEM/F12 (Gibco) supplemented with 2 mM L-glutamine (Sigma Aldrich), 1 × N2-supplement (Gibco), and 40 ng/ml recombinant human fibronectin (Sigma Aldrich), 1 µg/ml tetracycline (Sigma Aldrich) and 2 ng/ml recombinant human glial cell-derived neurotrophic factor (GDNF, R&D Systems).

For Ca²⁺-imaging, the cells were pre-differentiated for 48 h in cell culture flasks, detached and plated at a density of 20,000 cells and 30,000 cells per well on 0.1% PEI-coated 384-well and 96-well plates (Greiner Bio-One), respectively, for the Ca²⁺-imaging of single cells. The cells were further differentiated for another 7 days. 50% of the medium was exchanged every 2–3 days.

Cell culture of SH-SY5Y cells

SH-SY5Y cells were cultured as previously described (Att-off et al. 2016). Briefly, they were cultured in MEM supplemented with 10% fetal bovine serum (Gibco, 31330095), 1% non-essential amino acid solution (Gibco, 11140035), 2 mM L-glutamine (Gibco, 25030024), 100 µg/ml streptomycin, and 100 U/ml penicillin (Gibco, 15140122). For maintenance culture, SH-SY5Y cells were seeded at 27,000 cells/cm² in 75 cm² cell culture flasks (Corning). The cells were passaged once a week using TrypLE Express Enzyme (Gibco). SH-SY5Y cells were differentiated into a neuronal-like phenotype by exchanging the maintenance medium with differentiation medium consisting of DMEM/F12 (Gibco, 31330095) supplemented with 1 mM L-glutamine (Gibco, 25030024), 100 µg streptomycin/mL, 1 × N2-supplement (Gibco, 17502048) and 1 µM all-trans retinoic acid (RA, Sigma, R2625) 24 h after seeding. The cells were incubated in 100% humidity at 37 °C in air with 5% CO2.

LUHMES Ca²⁺-imaging

Ca²⁺-imaging was performed using HT Functional Drug Screening System FDSS/µCELL (Hamamatsu Photonics) at nominal 37 °C. The FDSS/µCell system enables the indirect recording of changes of [Ca²⁺], via a Ca²⁺-sensitive fluorescent dye. The fluorescence signal of a complete 384-well plate is acquired at once with a high-speed and high-sensitivity digital ImageX2 EM-CCD camera (Electron Multiplying Charge-Coupled Device, Hamamatsu Photonics), but with limited spatial resolution. Therefore, the software only determines the mean fluorescence signal of each well rather than of individual cells. For compound application, the integrated dispenser head with 384 pipette tips was used, which can add the test compound to all wells simultaneously. Cells were preincubated with Cal-520 AM (AAT Bioquest) at a concentration of 1 µM for 1 h at 37 °C. For recording, the medium was exchanged by a buffer solution containing [mM]: 135 NaCl, 5 KCl, 0.2 MgCl₂, 2.5 CaCl₂, 10 HEPES, and 10 D-glucose, pH 7.4. Test compound application was executed after obtaining a 1.5 min baseline recording. Where applicable, a second application was executed 4.5 min after the first application. The total recording never exceeded 8 min.

For Ca²⁺-imaging experiments with a higher resolution on the single-cell level, the Cell Observer (Carl Zeiss Microscopy) was used. The Ca²⁺-sensitive dye, the cell handling before the experiment, and the buffer were the same as described above for the experiments with the high-throughput FDSS/µCELL system. The recordings were performed with 2 × 2 binning and a 42 ms exposure time. The compounds were applied after a baseline recording of at least 10 s.

Ca²⁺ measurements in SH-SY5Y

To measure acute changes in the average [Ca²⁺] of a population, SH-SY5Y cells were examined in the 96-well plate fluorescence reader FlexStation II (Molecular Devices) using the fluorophore Fura-2AM (Molecular Devices). SH-SY5Y (35,000 cells/well; 109,375 cells/cm²) were seeded in maintenance culture medium in black 96-well plates with clear bottom (Corning, #3603). 24 h after seeding, maintenance medium was replaced with differentiation medium. After 72 h of differentiation, Fura-2AM dissolved in DMSO and diluted in KRH buffer (125 mM NaCl, 5 mM KCl, 1.2 mM MgSO₄, 1.2 mM
KRH$_2$PO$_4$, 2.0 mM CaCl$_2$, 6.0 mM D-glucose, and 25 mM HEPES (free acid), pH adjusted to 7.4 by 1.0 M NaOH) were added to the medium to a final concentration of 4 µM (Gustafsson et al. 2010). The plates were incubated for 30 min at 37 °C before cells were washed once with 200 µL KRH buffer. 90 µL of KRH buffer without or with 10 µM PNU-120596 (PNU) and/or 125 µM mecamylamine (Mec) and/or test chemicals in different concentrations for antagonist experiments were added to the Fura-2AM-loaded cells. The plate was again incubated for 20 min to allow full hydrolysis of the AM group before the experiment. The fluorescence was assessed at 37 °C in the fluorescence plate reader (FlexStation II; Molecular Devices) at two different excitation wavelengths, 340 nm for Ca$^{2+}$-bound Fura-2 and 380 nm for free Fura-2, and at 510 nm emission, every 3.1 s using bottom read settings. After 26–29 s of initial baseline recording of the fluorescence intensity, 10 µL of the compound dilution (10 times higher than the final concentration to the cells) was transferred automatically by the FlexStation II (“Flex mode”) to the cell plate wells (five wells per concentration) and the fluorescence intensity was monitored for another 150 s. The ratio of fluorescence intensity at 340/380 nm was determined and the mean values from the baseline recording before the addition of test compounds was set to zero. The acute change in the Ca$^{2+}$ influx after the addition of the compounds was quantified as the area under the curve (AUC) using the SoftMax Pro 4.8 software (Molecular Devices). All test compounds were dissolved in DMSO. Compounds were diluted in KRH buffer in 1:3 series, with 100 µM as the highest concentration. As a negative control, 0.1% DMSO in KRH buffer was used. Nicotine (11 µM) and KCl (30 mM) in KRH were used as positive controls. The Ca$^{2+}$ influx induced by DN-IMI was normalized to the response triggered by nicotine (11 µM) or KCl (30 mM).

### Oocyte recordings

The human α3 (GenBank: U62432.1), α4 (GenBank: L35901.1, silent base exchanges to reduce GC content), β2 (GenBank: X53179.1), and β4 (GenBank: U48861.1) nAChR subunits were synthesized using FragmentGene service by GeneWiz company and subsequently cloned in the pNKS2 vector (Gloor et al. 1995) using Gibson Assembly. The human α7 nAChR subunit was cloned in the pCDNA3.1 vector.

For the generation of the mRNA for injection, the plasmid DNAs of α3, α4, β2, and β4 were linearized with the NotI restriction endonuclease (New England Biolabs) and the plasmid DNA of α7 was linearized with the XbaI restriction endonuclease (New England Biolabs). The mRNAs of α3, α4, β2, and β4 were generated by in vitro transcription using the mMESSAGE mMACHINE SP6 Transcription Kit (Invitrogen). For the generation of α7 mRNA, the mMESSAGE mACHINE T7 Transcription Kit (Invitrogen) was used. For the separation of the DNA and mRNA, a phenol–chloroform extraction (Chomczynski and Sacchi 2006) was performed. The mRNA was then obtained by ethanol precipitation from the aqueous phase; for quantification, the BioPhotometer (Eppendorf) was used.

The recordings of human α7, α3β4, α4β2, and α4β4 nAChRs expressed in Xenopus laevis oocytes (EcoCyte Bioscience) were performed in two-electrode voltage-clamp mode using the Roboctocyte2 system and the corresponding software (version 1.4.1; Multi Channel Systems MCS). Prior to the recordings, the oocytes were maintained at 19 °C in modified Barths’s solution containing [mM]: 88 NaCl, 1 KCl, 0.33 Ca(NO$_3$)$_2$, 0.82 MgSO$_4$, 2.4 NaHCO$_3$, 0.41 CaCl$_2$, 5 Tris, 100 U/ml penicillin, 100 µg/ml streptomycin, pH 7.4.

To express human α7 nAChR, we injected 50 nl of mRNA solution (30 ng mRNA) per oocyte, using the Roboinject and the corresponding software (version 1.2.1; Multi Channel Systems MCS). The subunits of the heteromeric human α3β4 nAChRs and high-sensitivity (HS) (α4)$_2$(β2)$_2$ combination were injected in a ratio of 1:1 (α:β subunit) with an mRNA amount of 0.33 ng of α3 and 3.33 ng of β4 for α3β4, and 3 ng of α4 and 30 ng of β2 for α4β2. The mRNA for the subunits of the low-sensitivity (LS) (α4)$_2$(β2)$_2$ stoichiometry was injected in a ratio of 10:1 (α:β subunit) with 10 ng of α4 and 1 ng of β2. The subunits of the α4β4 nAChR subtype were injected in a ratio of 1:1 with 3.33 ng of α4 and 3.33 ng of β4. After mRNA injection, the oocytes were maintained for 3–6 days before recordings were performed. The experiments were executed in a ND96 buffer solution containing [mM]: 96 NaCl, 2 KCl, 1 MgCl$_2$, 1.8 CaCl$_2$, 5 HEPES, pH 7.4. The oocyte membrane potential was kept at −50 mV in all recordings. In experiments with α7, the compounds were applied for 5 s followed by a 60 s wash period. At the end of each recording, a reference application of 1 mM nicotine was performed. In experiments with heteromeric nAChRs, the compound was applied for 3 s, followed by a washout of 10 s, and an application of acetylcholine (ACh) for 1 s, which was followed by a washout of 60 s. The recordings for α3β4, α4β2 (HS), α4β2 (LS) and α4β4 were performed with 200 µM, 3 µM, 100 µM and 100 µM ACh, respectively. ACh was applied as an additional reference for run-down detection and positive control. Therefore, ACh was applied four times before the addition of the first compound concentration and after the application of each compound concentration. After the measurement of all compound concentrations, the last application was a reference exposure to nicotine with 1 mM for α3β4, 10 µM for α4β2 (HS), 100 µM for α4β2 (LS) and 100 µM for α4β4. The response response triggered by nicotine was used for the normalization of the compound effects.

For the antagonist experiments, DN-IMI was applied for 3 s after a 5 s baseline period. The application of DN-IMI...
was followed by a wash period of 70 s. At first, four control recordings were performed, followed by three recordings in the presence of each of the three antagonist concentrations in ascending order. Finally, three recordings were executed during the washout. DN-IMI was applied at 1 µM in recordings with α4β2 (HS) and at 30 µM in recordings with α3β4 and α7.

**Physiologically based toxicokinetic modeling**

A physiology-based toxicokinetic (PBTK) model for DN-IMI was established in the Simcyp Simulator V20 (Certara) using a previously published approach (Albrecht et al. 2019). Due to the lack of published human metabolism and exposure data for DN-IMI, an analog approach was used to inform the PBTK model using a compound, in our case atenolol, with known human pharmacokinetics and similar physicochemical properties. The input parameters for DN-IMI and atenolol are given in Table S8 and further details are found in Fig. S10.

**Data analysis**

For the high-throughput Ca2+ imaging data obtained in LUHMES cells, an offset correction using the FDSS software (version 3.2) was performed. Afterward, the data were exported and further analyzed with scripts written in R (version 3.6.3) (R Core Team 2020). The concentration–response curves were fitted using a log-logistic model described by Ritz et al. (2015), utilizing the R package drm with its function LL2.2() and LL2.3() with the following equation: $f(x) = d [1 + \exp(b(\log(x) - \hat{c}))]$ (Ritz et al. 2015). The logarithm of the half-maximal effective concentration (logEC50) between 0 and the upper limit (d), which was set to 1, is represented by $\hat{c}$. x denotes the concentration, and b stands for the slope parameter (Ritz et al. 2015). In cases with normalizations to responses induced by other compounds, the function LL2.3() was used with a variable upper limit (d; Ritz et al. 2015). The same equation was used to determine the half-maximal inhibitory concentration (logIC50). Then the logEC50 and logIC50 values were converted into the pIC50 and pEC50 values, which are the negative logarithms to base 10.

Concentration–effect responses in the SH-SY5Y [Ca2+]i were analyzed by the GraphPad Prism8.0 software using the four-parameter sigmoidal curve fit settings and the concentrations giving 50% increase in [Ca2+]i in relation to the nicotine response were estimated.

The single-cell Ca2+ imaging recordings were exported and analyzed in Fiji ImageJ (version 1.52i) to get the average fluorescence signal of each cell. These signals were further analyzed in R, where a threshold detection was performed to detect responding cells. For this, the offset was corrected by subtracting the mean of 20–65% of the fluorescence signal of the pre-application period from the recording, to be robust against spontaneous activity. The threshold was defined as mean + 3 * SD of the negative control recordings, during the detection phase of 6.5 s during the application.

The baseline correction of voltage-clamp oocyte recordings was performed with the Roboocyte2 + software (version 1.4.3; Multi Channel Systems MCS, Germany). The maximal current influx and further analysis were executed in scripts written in R. In the antagonist experiments with oocytes, the maximal inward current was determined for the last response of each period (control, three antagonist concentrations, and washout).

The following R packages were utilized for data handling: cowplot (Wilke 2019), dplyr (Wickham et al. 2020), drc (Ritz et al. 2015), ephys2 (Danker 2018), ggplot2 (Wickham 2016), htmlwidgets (Vaidyanathan et al. 2019), lemon (Edwards 2019), magic (Ooms 2020), magrittr (Bache and Wickham 2014), matrixStats (Bengtsson 2020), modelr (Wickham 2020), multcomp (Hothorn et al. 2008), plotrix (Lemon 2006), proto (Grothendieck et al. 2016), and tidyverse (Wickham et al. 2019).

Unless mentioned differently, values are presented as means ± SEM. Experiments were usually performed with at least three technical replicates per condition. Detailed data on pEC50, pIC50, and numbers of experimental repetitions are given in supplementary tables. Unless mentioned differently, statistical significance was defined as $P < 0.05$ and was determined by one-way ANOVA with Dunnett’s post hoc test as indicated. To determine benchmark concentrations (BMC), and their upper and lower 95% confidence intervals (BMCL, BMCU), the BMC online software of UKN was used (Krebs et al. 2020).

**Results and discussion**

**Activation, inhibition, and desensitization of nAChRs functionally expressed in LUHMES and SH-SY5Y cells**

**Activation of nAChRs on LUHMES cells by DN-IMI**

LUHMES neurons express functional α7 and non-α7 nAChRs, and they have proven useful for the characterization of different neonicotinoids like IMI by high-throughput Ca2+ imaging (Loser et al. 2021a). We used this system here for the functional characterization of the two IMI metabolites DN-IMI and IMI-olefin (Fig. 1A). Both metabolites produced clear signals (Fig. 1B, C). A quantification of [Ca2+]i responses yielded a pEC50 of 6.6 for DN-IMI (Fig. 1D). DN-IMI appeared at least as potent as ACh and nicotine (pEC50 values of ~ 6.0 in LUHMES neurons) (Loser et al. 2021a).
Fig. 1 Effect of desnitro-imidacloprid (DN-IMI) and imidacloprid-olefin (IMI-olefin) on LUHMES neurons. A Chemical structures of imidacloprid (IMI) and its two metabolites desnitro-imidacloprid (DN-IMI) and imidacloprid-olefin (IMI-olefin). B–F LUHMES neurons were differentiated for 9 days before they were loaded with an [Ca\(^{2+}\)]\(_i\) indicator dye and used for \([\text{Ca}^{2+}]_i\)-imaging. B, C The cells cultivated in 384-well plates were exposed to various concentrations of DN-IMI and IMI-olefin, and exemplary recordings of the fluorescence signal from a whole well are shown. D The fluorescence data (peak amplitude) of multiple experiments were quantified and normalized to the maximal response stimulated by DN-IMI (means ± SEM are displayed). The significance of the responses triggered by IMI-olefin was determined between control recordings and the responses evoked by IMI-olefin (*: \(p < 0.05\)). For DN-IMI, a sigmoid curve was fitted to the data, and a pEC\(_{50}\) value of 6.6 ± 0.03 was obtained as a potency estimate. Note the treatment scheme (upper left corner), illustrating the experimental design. E, F LUHMES cultures in 96-well plates were used to image the [Ca\(^{2+}\)]\(_i\) responses of single cells with a fluorescent microscope. Regions of interest were assigned for all individual cell bodies in the image section. E \([\text{Ca}^{2+}]_i\)-imaging traces of the responses of individual cell bodies are shown after exposure to DN-IMI (10 µM). F The percentage of cells that responded with a clear fluorescence increase (= rise in [Ca\(^{2+}\)]\(_i\)) to different concentrations of DN-IMI was determined. Note the treatment scheme (upper left corner), illustrating the experimental design. Detailed data on n numbers are listed in Tables S6.
et al. 2021a). These signaling data are in line with published binding data that suggest a similar affinity of DN-IMI and nicotine for mammalian nAChRs (Tomizawa and Casida 1999; D’Amour and Casida 1999; Tomizawa et al. 2000).

For IMI-olefin, the pEC_{50} was not reached within the measurement range (≤ 100 μM), but a significant response (around 15% of the maximal response to DN-IMI) was found at 30–100 μM. Thus, the potency of IMI-olefin was similar to that of its parent compound IMI (Loser et al. 2021a). Our observations on signaling potency are consistent with the literature data for differences in binding affinity to mammalian nAChRs (Chao and Casida 1997; Tomizawa and Casida 1999; D’Amour and Casida 1999; Tomizawa et al. 2000).

The data on DN-IMI were confirmed by a different analytical method. Instead of the whole-culture-based high-throughput [Ca^{2+}]_{i} assay, we used traditional time-lapse fluorescence microscopy to quantify responses of individual cells (Fig. 1E). We found here a percentage of responsive cells of ~ 80%. This population was similar in size to that of its parent compound IMI (Loser et al. 2021a). The quantification of single-cell responses confirmed the sub-micromolar potency of DN-IMI and suggested that the majority of all cells responded functionally to the IMI metabolite (Fig. 1F).

**Activation of α7 and non-α7 nAChRs on LUHMES and SH-SY5Y cells by DN-IMI**

There is a large variety of nAChR subtypes with distinct functions in the nervous system. To get initial information, we examined whether the human α7 nAChR is affected by DN-IMI. This Ca^{2+} permeable receptor is widely distributed in the central nervous system and involved in the modulation of neurotransmitter release (McGehee et al. 1995; Gray et al. 1996; Alkondon et al. 1999; Gotti et al. 2006; Zoli et al. 2015). We utilized PNU-120596 (PNU), a selective positive allosteric modulator of the α7 nAChR, to slow down the α7 nAChR inactivation and enable thereby the detection of the α7 nAChR-mediated response in Ca^{2+}-imaging (Hurst et al. 2005; Dickinson et al. 2007; Ng et al. 2007; Grønlien et al. 2007; Papke et al. 2009; Williams et al. 2011; Chatzidaki et al. 2015; Larsen et al. 2019). The response of LUHMES neurons to DN-IMI was strongly enhanced and prolonged in the presence of PNU (Fig. 2A). A quantification at multiple DN-IMI concentrations showed that this effect is less pronounced at sub-maximal receptor stimulation (Fig. 2B). The maximal amplitude triggered by DN-IMI was increased by PNU by around 40%. This strongly suggests the activation of α7 nAChRs. These data are fully in line with findings showing the enhancement of neonicotinoid effects by PNU in LUHMES neurons (Loser et al. 2021a). The activation of non-α7 nAChRs at low concentrations of DN-IMI (0.03–0.3 μM) is most likely the reason for an absence of PNU enhancement in the low concentration range.

To further support these findings, we examined the effect of DN-IMI on a second human cell system. SH-SY5Y neuroblastoma cells predominantly express the α7 nAChR subtype, together with α3-containing receptors (Loser et al. 2021a). Therefore, they show little response to neonicotinoids or nicotine in the absence of PNU, and also DN-IMI only triggered small responses reaching about 44% of the maximal response obtained in the presence of PNU (Fig. 2C). In this experimental setup (presence of PNU), DN-IMI led to a strong, concentration-dependent [Ca^{2+}]_{i} response with half-maximal responses at about 0.3 μM, a peak at ~ 3 μM, and declining responses at even higher concentrations (Fig. 2C). The maximal response triggered by DN-IMI was roughly similar to the one evoked by nicotine. The strong signal increase in the presence of PNU is in line with our results for LUHMES.

We also examined the effect of IMI-olefin in the absence and presence of PNU on [Ca^{2+}]_{i} of LUHMES neurons (Fig. S1A), and we observed a strong enhancement of the signal. This allowed for the determination of a pEC_{50} (5.5 in the presence of PNU) (Fig. S1B). The significant increase of the responses indicates the activation of human α7 nAChRs by IMI-olefin, but with a significantly lower potency compared to DN-IMI.

**Inhibition of DN-IMI-evoked responses of LUHMES and SH-SY5Y cells by nAChR antagonists**

We used a pharmacological approach to verify that the signaling ([Ca^{2+}]_{i}) effect of DN-IMI is mediated exclusively by nAChRs. For this purpose, LUHMES cells were pretreated with several well-known nAChR antagonists. Tubocurarine (Tubo) (Jonsson et al. 2006) antagonized the responses evoked by DN-IMI with a pIC_{50} of 5.9 (Fig. 3A, C). Tubo completely blocked the response at 100 μM, indicating that the entire DN-IMI-evoked Ca^{2+}-signaling was mediated by nAChRs. The obtained pIC_{50} value is comparable to the values determined for several nAChR agonists in experiments with LUHMES (Loser et al. 2021a).

To further substantiate this finding, we utilized the non-competitive nAChR antagonist mecamylamine (Mec) (Papke et al. 2008; Capelli et al. 2011). It blocked the DN-IMI-induced response in LUHMES neurons with a pIC_{50} of 6.8 (Fig. 3B, C), which is in line with the literature data of 6.6 for human α3β2 nAChRs (Chavez-Noriega et al. 2000). We also used Mec in the SH-SY5Y cultures, and the [Ca^{2+}]_{i} responses induced by DN-IMI were strongly blocked (Fig. 2D). This confirmed that also in this cell model, DN-IMI signaling was strictly dependent on nAChRs.
To further investigate the agonism of DN-IMI on nAChRs on LUHMES, we researched the effect of the antagonist methyllycaconitine (MLA), which is highly potent (low nM range) on α7 nAChRs compared to other nAChR subtypes (Puchacz et al. 1994; Gopalakrishnan et al. 1995; Palma et al. 1996; Buisson et al. 1996; Capelli et al. 2011). MLA inhibited the response to DN-IMI with a pIC50 of 6.8 (Fig. 3D, F), which is comparable to the value obtained for nicotine with LUHMES (Loser et al. 2021a). The pIC50 is similar to the literature data for human α4β2 and α6-containing (α6/3β2β3) nAChRs (Capelli et al. 2011). This (relatively low) potency of MLA in LUHMES indicates the involvement of non-α7 nAChRs in the [Ca2+]i response evoked by DN-IMI.

Finally, we applied the nAChR antagonist MG 624 (Gotti et al. 2000; Capelli et al. 2011) on LUHMES neurons. The resulting pIC50 of 6.8 (Fig. 3E, F) is comparable to the pIC50 of nicotine obtained with LUHMES neurons (Loser et al. 2021a) and previously reported data for α4β2, α3β4, α7, and α1β1δε nAChRs (Capelli et al. 2011).
In summary, the antagonist data demonstrate the activation of nAChRs by DN-IMI and indicate the involvement of different nAChR subtypes.

Desensitization of cholinergic responses of LUHMES and SH-SY5Y cells by DN-IMI

An important feature of nAChRs is desensitization. This is the inactivation of the receptor during agonist exposure or upon closely timed repeated agonist applications. Thus, even in the presence of an agonist, the receptor can stop the signaling and may not be activated again within a certain period after an initial stimulation (Fenster et al. 1997; Quick and Lester 2002; Paradiso and Steinbach 2003; Lester 2004; Rollema et al. 2010; Marks et al. 2010; Capelli et al. 2011; Papke et al. 2011; Campling et al. 2013; Eaton et al. 2014; Arias et al. 2015; Rollema and Hurst 2018). The desensitization of a receptor is typically caused by an agonist concentration that activates the receptor, but it can also occur at low concentrations that are not sufficient to activate it (Fenster et al. 1997; Paradiso and Steinbach 2003; Lester 2004; Rollema et al. 2010; Capelli et al. 2011; Arias et al. 2015; Rollema and Hurst 2018). As our previous results indicate an agonistic effect of both IMI metabolites, we investigated whether they would also desensitize the nAChRs on LUHMES neurons. In these experiments, the metabolites were pre-applied at various concentrations and then the response of LUHMES neurons was triggered by the exposure to nicotine and measured by Ca²⁺-imaging. The pretreatment led to a pronounced reduction of the responses.
nicotinic signaling (Fig. 4A, B). The corresponding concentration–response curves yielded pIC$_{50}$ values of 6.9 for DN-IMI and 4.9 for IMI-olefin (Fig. 4C). The pIC$_{50}$ of IMI-olefin is comparable to the effects of its parent compound IMI and other neonicotinoids (Loser et al. 2021a). The pIC$_{50}$ of DN-IMI is comparable to pIC$_{50}$ values reported for the desensitizing effect of nicotine on human α4β2, α4β4, and α3β4 nAChRs (Fenster et al. 1997; Lester 2004; Capelli et al. 2011). Thus, DN-IMI was more potent than several neonicotinoids (pIC$_{50}$s of ~5.4) (Loser et al. 2021a) and IMI-olefin at attenuating the response evoked by nicotine. For confirmation of the desensitization in a different cell model, we used SH-SY5Y cells. In addition, here, pretreatment with DN-IMI reduced/abolished the response to nicotine in the submicromolar range. This effect was clearly more potent than the desensitization observed by IMI and another neonicotinoid pesticide, acetamiprid (Fig. S2). Thus, desensitization by neonicotinoids was confirmed in a second cell model, and the particularly high potency of DN-IMI was reproduced.

To confirm that the desensitizing effect was not specific for nicotine stimulation, we used the endogenous nAChR agonist ACh and the selective non-α7 nAChR agonist ABT 594 for stimulation (Donnelly-Roberts et al. 1998; Michelmore et al. 2002) (Fig. 4D, E). Here, we observed pIC$_{50}$ values of ~7.4 for the desensitization (Fig. 4F). This high potency is in agreement with other observations that desensitization of nAChR can occur at lower concentrations than required for activation (Fenster et al. 1997; Paradiso and Steinbach 2003; Lester 2004; Rollema et al. 2021a).
The large difference in potency of DN-IMI and its parent compound IMI and other neonicotinoids is consistent with the literature data for potency differences in binding assays with mammalian nAChRs (Chao and Casida 1997; Tomizawa and Casida 1999; D’Amour and Casida 1999; Tomizawa et al. 2000).

In summary, DN-IMI desensitized nAChRs in the nM range, and this may be of toxicological significance, as nAChR signaling plays an important role in the central nervous system (Alkondon et al. 1999; Champtiaux et al. 2003; Levin et al. 2006; Gotti et al. 2006; Zoli et al. 2015).

### Activation of human α4β2, α7, and α3β4 nAChRs by DN-IMI

To verify an agonistic effect of DN-IMI on the physiologically important neuronal nAChR subtypes α4β2, α7, and α3β4, we expressed each of them in *Xenopus laevis* oocytes and performed two-electrode voltage-clamp recordings (Fig. 5A).
First, we focused our experiments on the α4β2 receptor, which can assemble in two different stoichiometries. The high-sensitivity (HS) variant (two α4 subunits and three β2 subunits) has been reported to have a pEC50(ACh) of ~5.7 in the Xenopus laevis oocyte expression system, while the low-sensitivity variant (three α4 subunits and two β2 subunits) had a pEC50(ACh) of ~4.1 (Bermudez and Moroni 2006; Moroni et al. 2006; Jonsson et al. 2006; Carbone et al. 2009; Mineur et al. 2009; Mazzaferro et al. 2011; Harpste et al. 2011; Li et al. 2011; Benallegue et al. 2013). In our system, we found for the α4β2 (HS) receptor a pEC50(ACh) of ~5.7 (Fig. S3A, B). For nicotine, we found a pEC50 of 6.3, in line with the literature data (Moroni et al. 2006). DN-IMI yielded a relative pEC50 of 6.3 (Fig. 5B, C). The data show a high potency for this nAChR subtype; our data suggest that DN-IMI has a similar potency but slightly lower efficacy (64% of full stimulation) than nicotine (Fig. S3C, D). Its parent compound IMI did not trigger a concentration-dependent activation of the receptor in the tested concentration range (≤ 100 µM). For control purposes, we applied DN-IMI (30 µM) to Xenopus laevis oocytes without additional receptor expression (injection of water without mRNA).

In this experimental setup, we did not detect any current responses (n = 5, data not shown). These findings show that DN-IMI only triggered inward currents via the activation of the heterologously expressed human nAChRs. This was further confirmed by antagonist experiments, where the response of the human α4β2 (HS) receptor to DN-IMI was concentration-dependently and reversibly blocked by the non-competitive nAChR antagonist Mec (Fig. S4).

To verify an agonistic effect of DN-IMI and IMI-olefin on human α7 nAChRs, we expressed this nAChR subtype in Xenopus laevis oocytes and performed two-electrode voltage-clamp recordings (Figs. 5D and S5). DN-IMI had a relative pEC50 of 4.5 with a lower efficacy than nicotine (Figs. 5D and S5A, D). Compared to nicotine, DN-IMI thus showed a slightly higher potency and a partial agonistic effect (estimated maximum of ~81% of the maximal response to nicotine) on human α7 nAChRs, well in line with our Ca2+-imaging data (Fig. 2B, C). IMI-olefin and its parent compound IMI also stimulated significant inward currents but with a lower potency and efficacy than DN-IMI (Figs. 5D and S5B, D). The results for IMI match our previous findings with LUHMES and SH-SY5Y neurons (Loser et al. 2021a). The application of nicotine yielded a pEC50 of 3.9 (Figs. 5D and S5C, D), which is comparable to the literature data (Briggs et al. 1995). As an internal consistency check, we performed antagonist experiments, where the DN-IMI-triggered response of the human α7 nAChR was concentration-dependently and reversibly blocked by the selective α7 receptor antagonist MLA (Fig. S4).

As a third approach, we investigated the effects of DN-IMI on human α3β4 nAChRs expressed by Xenopus laevis oocytes. The application of nicotine and ACh resulted in pEC50s of 4.0 and 3.8 (Figs. 5E and S6A, B, D), respectively, which are both comparable to the literature data (Wang et al. 1996; Nelson et al. 2001; Jonsson et al. 2006). The addition of DN-IMI to oocytes expressing human α3β4 nAChR yielded a relative pEC50 of 4.9 (Figs. 5E and S6C, D). IMI evoked small but significant inward currents in a concentration-dependent manner (Figs. 5E and S6D–F). Responses of the human α3β4 nAChR triggered by DN-IMI
were concentration-dependently and reversibly blocked by the nAChR antagonist Tubo (Fig. S4).

For the further characterization of DN-IMI on individual receptors, we investigated the effects of DN-IMI and IMI on the low-sensitivity variant of α4β2 (LS) and on α4β4 nAChRs. DN-IMI yielded pEC50 of 5.3 for α4β2 (LS) and 5.5 for α4β4 (Fig. S7). IMI did not trigger a concentration-dependent activation of these two nAChR subtypes in the tested concentration range (≤ 100 µM).

Having obtained data on nicotine and DN-IMI for nAChR subtypes, we used them for a comparison of their potencies. For this purpose, we determined the absolute EC25 values (Fig. 6A). These data suggest that DN-IMI and nicotine were about equipotent on the α4β2 (HS) nAChR (less than half a log-step difference). On the other receptors, DN-IMI appeared slightly more potent than nicotine (about 0.6 log-steps). To understand differences between experimental systems or possibly to predict toxicological consequences for brain areas with different receptor expression patterns, it was interesting to compare apparent (functional) receptor affinities: this showed that both ligands were more potent on the α4β2 (HS) nAChR than on other subtypes (> 1 log-step for DN-IMI; > 2 log-steps for nicotine), while there was no difference between, e.g., α7 and α3β4 (Fig. 6B). This might explain mixed responses, e.g., on LUHMES cultures that express all these receptor types, and it provides an explanation for differences between, e.g., SH-SY5Y cells and LUHMES (the former cells predominantly express α7 receptors but also α3-containing receptors (Loser et al. 2021a)).

In summary, the metabolite DN-IMI exhibits significantly higher potency and efficacy on the human nAChR subtypes than its parent compound IMI. We performed extensive molecular docking studies of nicotine, IMI, DN-IMI, and IMI-olefin to further substantiate the experimental findings from oocytes and to provide a molecular explanation. The modeling results suggest a positioning of DN-IMI similar to that of nicotine at the binding sites of two nAChR subtypes. In contrast, IMI and IMI-olefin tend to adopt inverted and less favorable binding poses (Figs. S8 and S9). The docking studies thus provide a potential explanation for the lower signaling potency of these two compounds compared to DN-IMI.

**Exposure considerations and in vitro-to-in vivo comparisons**

While the above approaches inform on potential hazards by DN-IMI, the interpretation of the data and their use for risk assessment requires some understanding of concentrations to be reached in human tissues/body fluids. Due to the lack of more direct human data, we built a physiology-based toxicokinetic (PBTK) model to predict the plasma concentrations of DN-IMI. Because of the limited availability of human metabolism and exposure data for DN-IMI, the model construction was based on data from atenolol, a compound with similar physicochemical properties, and with well-known human pharmacokinetics. As DN-IMI-specific parametrization of the model, we used metabolic turnover data from human primary hepatocytes and physicochemical properties of DN-IMI as predictors for passive membrane permeability and protein binding (Table S8). As input (oral exposure), we used 0.016 mg DN-IMI/kg body weight.
amount corresponds to 10% of the value used earlier for IMI PBTK modeling (Loser et al. 2021a). Our rationale was that DN-IMI can reach about 10% of the IMI content in fruits, vegetables, and cereals (see the introduction for reference).

Under these conditions, the model predicted average plasma concentrations of around 50 nM and peak concentrations in a subfraction of the human population of at least 100 nM (Fig. S10A). The plasma concentrations predicted for atenolol from our PBTK model were in good agreement with measured data found in the literature (Fig. S10B). We see this as an indication of a good predictive capacity of our model. As the central nervous system is a main target tissue of DN-IMI, we also predicted brain concentrations. They were even slightly higher than the plasma concentrations (Fig. S10C). It is likely that the free diffusion of the compound through the blood–brain barrier also predicts a free distribution into the fetus. It is, therefore, reasonable to assume that also fetal brains would be exposed to DN-IMI at concentrations up to the three-digit nM range.

BMC modeling of our [Ca^{2+}], signaling and single nAChR data showed 20% response (in different systems) at about 100–300 nM of DN-IMI (Tables S9 and S10). Such concentrations are close to the ones reachable in some subjects by dietary exposure. While such concentrations may not be reached for the average of the population, the gap between realistic internal exposure levels and the minimal effect concentration is less than tenfold. This marginal safety buffer is eliminated, if receptor desensitization is considered as an effect parameter: the BMC for this endpoint was at ~17 nM (Table S11, for a 20% effect). Such concentrations may be reached by the consumption of food derived from crops treated with IMI. Notably, the desensitizing effect may be equally problematic for normal brain function and neuronal development, as the direct activation of the nAChRs.

To conclude these preliminary risk assessment considerations, it is important to consider that exposure to DN-IMI may also occur through the metabolism of IMI after it has been ingested. From rodent experiments, it is clear that DN-IMI is generated after exposure to IMI, and that the endogenous metabolite DN-IMI distributes to the brain (Chao and Casida 1997; Ford and Casida 2006). In addition, goat data suggest that IMI is converted to DN-IMI (about 25% of the IMI dose recovered in the liver) (Anon 2006). In rabbits, DN-IMI was excreted in the urine after exposure to IMI (Vardavas et al. 2018), and this agrees well with human biomonitoring data that identified high (several fold higher than IMI) levels of DN-IMI in urine (Wang et al. 2020).

If one assumes that 10% of ingested IMI is converted to DN-IMI, then the endogenously formed metabolite may reach levels of a similar magnitude as those generated from direct ingestion of the metabolite (assuming that the intake of IMI is 10 times higher than that of DN-IMI (input parameter of our PBTK model, based on food consumption data)). Therefore, a mixed exposure to IMI, DN-IMI, but also other metabolites, either produced endogenously (see PBTK model) or exogenously (see introduction), seems to be realistic and may lead to the summation of their adverse effects on the organism.

Even though such considerations of potential internal exposure are consistent with the literature data, they need to be considered as very preliminary. There is still considerable uncertainty on the human metabolism. It is not known which percentage of IMI is metabolized to DN-IMI within the liver and whether other tissues also contribute to the metabolism. The situation is complex, as several competing enzymes may oxidize or reduce IMI. Besides cytochrome P450 enzymes, there is evidence for the contribution of cytosolic aldehyde oxidases (Dick et al. 2005; Swenson and Casida 2013; Vardavas et al. 2018). These enzymes show high species variation in their expression and activity (Dick et al. 2005; Pryde et al. 2010). Considering that humans express relatively high levels of aldehyde oxidase, data from animals cannot be easily translated to humans, and experiments are ongoing to better quantify IMI metabolism by different cell compartments.

Conclusions and outlook

The present study shows that the IMI metabolite DN-IMI potently (at sub-micromolar concentrations) affects human nAChRs. This was found both in neuronal cultures and in defined individual receptor subtypes expressed in *Xenopus laevis* oocytes. The evidence from all systems clearly indicates a much higher potency of DN-IMI relative to its parent compound IMI. The comparative data show that the desnitro metabolite is equipotent to nicotine, while another IMI metabolite, IMI-olefin, rather was equipotent to IMI. The study on DN-IMI showcases the role of metabolism for human neurotoxicology, as it demonstrates that a particular metabolite can be several orders of magnitude more potent as a neuronal signaling disrupter (desensitization) than its parent compound. This may have consequences for the risk assessment of the parent compound and for the need of additional data on metabolite generation in the environment and in man. Our preliminary modeling suggests that bioactive, potentially toxic DN-IMI concentrations may be reached by nutritional exposure in the normal (not professionally exposed) population.

Median lethal dose (LD$_{50}$) studies with mice showed that DN-IMI (LD$_{50}$: 6–24 mg/kg) is more toxic than its parent compound IMI (LD$_{50}$: 35–50 mg/kg) (Chao and Casida 1997; Tomizawa et al. 2000, 2001) and IMI-olefin (no lethality at the highest tested dose of 50 mg/kg) (Chao and Casida 1997). Little information is available on more subtle forms of neurotoxicity, and to our knowledge, no data are available on the potential developmental neurotoxicity of DN-IMI.
The latter is important, considering that nicotine is an established developmental neurotoxicant (Levine et al. 1993; Le Sage et al. 2006; Aschner et al. 2017). The former is relevant, as different nAChR subtypes are present on, e.g., dopaminergic neurons and play an important role in the modulation of the electrical activity and neurotransmitter release (Rapier et al. 1988; Grady et al. 1992; Quik and Kulak 2002; Mameli-Engvall et al. 2006; Quik and Wonnacott 2011; de Kloet et al. 2015). Thus, substance-induced disturbances of nicotinic signaling can have an impact on the functioning, plasticity, and development of the nervous system (Wheeler and Cooper 2004; Welsby et al. 2006; Slotkin et al. 2006; Ziviani et al. 2011; Lozada et al. 2012; de Kloet et al. 2015; Romoli et al. 2019).

Several studies reported that the binding affinity of DN-IMI to mammalian or chicken nAChRs was similar to the affinity of nicotine and clearly higher than the one of its parent compound IMI (Chao and Casida 1997; Tomizawa and Casida 1999, 2000; D’Amour and Casida 1999; Tomizawa et al. 2000). Our functional data using a physiological signaling response in human neurons are in line with these observations. DN-IMI triggered [Ca2+]i responses at concentrations ≥ 100 nM, i.e., it was at least two orders of magnitude more potent than its parent compound (Loser et al. 2021a). These findings were further supported by oocyte recordings, which showed an agonistic effect of DN-IMI on human α7 and several non-α7 nAChRs. DN-IMI activated α4β2 (HS) receptors at 20-fold lower concentrations than α7 and α3β4 nAChRs. This potency difference on α7 and α3β4 vs α4β2 (HS) is also seen for nicotine. Such relative receptor preferences may be responsible for a selective toxicity on certain brain regions or neuronal functions, and future studies should also include assays on non-neuronal nAChR.

In desensitization experiments with LUHMES, the pretreatment with DN-IMI inhibited the subsequent activation of the nAChRs at concentrations ≥ 10 nM (BMR10, Table S11), which is ~70 times more potent compared to the effects of IMI (Loser et al. 2021a). The more potent desensitization effect of DN-IMI in comparison with IMI was confirmed in SH-SY5Y neurons (Fig. S2). After prolonged agonist exposure, nicotinic receptors desensitize by adopting a high-affinity and agonist-bound, non-conducting conformation (Nemecz et al. 2016; Morales-Perez et al. 2016). This may adversely affect normal neuronal function and neurodevelopment.

For adverse outcome pathways (AOPs), it is important to understand the molecular initiating events (MIEs) both for parent compounds and also for the relevant metabolites formed (Leist et al. 2017). Until now, few such cases have been fully resolved, as the focus in neurotoxicology has either been on toxicants acting independent of metabolism, e.g., rotenone or vinca alkaloids (Delp et al. 2018b, 2021), or on compounds that act by a single toxic metabolite, without any effect of the parent, such as methylphenylpyridinium (Schildknecht et al. 2015; Terron et al. 2018) or methylmercury (Aschner et al. 2017). In many other cases, the target is little defined (e.g., for solvents or acrylamide). In this context, mechanistic studies on neonicotinoids and their metabolites should eventually provide an explanation for different potencies and activity spectra of all metabolites on various nAChRs. While we provide here evidence for the stimulation of nAChRs and on the attenuation of signaling (by desensitization) as MIEs, it is not possible to predict the most relevant adverse outcome. The reason for this is that nicotinic receptors are widespread throughout the central nervous systems and they are crucial for a large panel of higher order nervous system functions (Levin et al. 2006; Gotti et al. 2006; Zoli et al. 2015; Terry and Callahan 2019).

Concerning the understanding of the MIE, we used molecular docking studies to provide a rationale for the experimental findings. The availability of several X-ray structures with co-crystallized neonicotinoids has facilitated the establishment of a robust docking model (Ihara et al. 2008, 2014; Loser et al. 2021a). In the present work, we focused on the overlap of the pesticide N-heteroaromatic ring with the pyridine ring of nicotine. The comparison with published studies showed good accuracy of our model. Structural alignments of these complexes and docking studies at human nAChRs demonstrate that the electronegative moiety in IMI can contribute to a flip of the imidazolidine ring in the binding pocket. We demonstrate here that this is less likely to happen with DN-IMI. This feature may explain its higher affinity/potency. Our binding hypothesis is supported by ranking via different docking scores, binding free energy approximates, and comparisons of nicotinoids and neonicotinoids bound to homologous proteins. This gives a rationale for the functional differences of neonicotinoids and nicotine that were reported for cell experiments with LUHMES and SH-SY5Y cells (Loser et al. 2021a). These studies are still mainly qualitative, and their applicability domain is most likely narrow (applying only to the compounds of this study). However, our approach forms the basis for the development of a more powerful and refined model in the future. Eventually, this might then be able to quantitatively predict MIEs for the dozens of neonicotinoid metabolites found in food. Such a model might distinguish, e.g., high- vs. low-affinity ligands or discriminate between agonists and antagonists.

Further research is also needed to elucidate whether the signaling disturbances revealed here have lasting effects on neuronal function. It has been reported that other nAChR agonists (including nicotine) may affect nervous system plasticity and development (Levin et al. 1993; Wheeler
and Cooper 2004; Welsby et al. 2006; Slotkin et al. 2006; Ziviani et al. 2011; Lozada et al. 2012; Romoli et al. 2019). Epidemiological studies are quite scarce, but some general developmental/neurological effects have been reported for neonicotinoids used in agriculture or anti-tick sprays (Ciminio et al. 2017).

Some other compounds that evoke disturbances of neuronal network activity without causing structural changes have been reported to induce developmental neurotoxicity (DNT). Examples are 3,4-methylenedioxymethamphetamine (MDMA, ecstasy), heroin, or nicotine (Levin et al. 1993; Slikker Jr et al. 2005; LeSage et al. 2006; Dwyer et al. 2009; Slotkin et al. 2016; Aschner et al. 2017). Moreover, compounds for example methylmercury and lead can have severe effects on the developing brain, although they have a low neurotoxicity for adults (Grandjean and Landrigan 2014). These examples make it conceivable that neonicotinoids and their metabolites such as DN-IMI may exhibit a DNT risk. However, a transfer of knowledge from one compound (e.g., nicotine) to others (e.g., DN-IMI) holds the risk of uncertainties (Rovida et al. 2020). Therefore, further mechanistic studies are needed to address the difficult question of a DNT hazard of DN-IMI and other neonicotinoid metabolites like a descyano metabolite of thiacloprid, which has also been reported to exhibit a higher affinity for mammalian and chicken nAChRs than its parent compound (Tomizawa and Casida 2000; Tomizawa et al. 2000).

Supplementary Information This online version contains supplementary material available at https://doi.org/10.1007/s00204-021-03168-z.

Acknowledgements This work was supported by the Land Berlin (LTB-P769), the InViTe PhD program and the 3Rs Center of the Baden-Wuerttemberg Ministry for Science, Research and Art (MWK Baden-Wuerttemberg), EFSA, the DK-EPA (MST-667-00205), the Swedish Research Council (VR-2018-03269), the University of Konstanz and Stockholm University. It has received funding from the European Union’s ERASMUS+ program, the DFG (Research Training Group GRK 2338, P01), and the Horizon 2020 research and innovation program under grant agreements no. 681002 (EU-ToxRisk), no. 964537 (RISK-HUNT3R), no. 964518 (ToxFree) and no. 825759 (ENDpoiNTs). This work received financial support from the State Ministry of Baden-Wuerttemberg for Economic Affairs, Labour and Tourism.

Author contributions DL: conceived or designed the study, performed research, analyzed data, and wrote the paper. KG and JB: performed research, analyzed data, and wrote the paper. MH, YJ, CB, and PW: performed research and analyzed data. YH, GE, AN, TD, CM, and IG: contributed new methods or models. AF, SB, UK, and ML: conceived of or designed the study and wrote the paper.

Funding Open Access funding enabled and organized by Projekt DEAL.
Bass C, Denholm I, Williamson MS, Nauen R (2015) The global status of insect resistance to neonicotinoid insecticides. Pestic Biochem Physiol 121:78–87. https://doi.org/10.1016/j.pestbp.2015.04.004

Benallegue N, Mazzaferrro S, Alcaino C, Bermudez I (2013) The additional ACh binding site at the α4(+)/α4(−) interface of the (α4β2)2α4 nicotinic ACh receptor contributes to desensitization. Br J Pharmacol 170:304–316. https://doi.org/10.1111/bph.12268

Bengtsson H (2020) matrixStats: functions that apply to rows and columns of matrices (and to vectors). R package version 0.56.0. https://CRAN.R-project.org/package=matrixStats

Berheim EH, Jenks JA, Lundgren JG et al (2019) Effects of neonicotinoid insecticides on physiology and reproductive characteristics of captive female and fawn white-tailed deer. Sci Rep 9:4534. https://doi.org/10.1038/s41598-019-40994-9

Bermudez I, Moroni M (2006) Phosphorylation and function of α4β2 receptor. J Mol Neurosci 30:97–98. https://doi.org/10.1385/JMN:30:1:97

Briggs CA, McKenna DG, Piattina-Kaplan M (1995) Human α 7 nicotinic acetylcholine receptor responses to novel ligands. Neuropharmacology 34:583–590. https://doi.org/10.1016/0028-3908(95)00208-5

Brown LA, Ibara M, Buckingham SD et al (2006) Neonicotinoid insecticides display partial and super agonist actions on native insect nicotinic acetylcholine receptors. J Neurochem 99:608–615. https://doi.org/10.1111/j.1476-5381.2008.00104.x

Brill M, Spreng A-S, Gutbier S et al (2020) Incorporation of stem cell-derived astrocytes into neuronal organoids to allow neuro-glial characterization of the recombinant human neuronal nicotinic acetylcholine receptor. J Mol Neurosci 30:97–98. https://doi.org/10.1385/JMN:30:1:97

Bruijl M, Spreng A-S, Gutbier S et al (2020) Incorporation of stem cell-derived astrocytes into neuronal organoids to allow neuro-glial characterization of the recombinant human neuronal nicotinic acetylcholine receptor. J Mol Neurosci 30:97–98. https://doi.org/10.1385/JMN:30:1:97

Champtiaux N, Gotti C, Cordero-Erausquin M et al (2003) Subunit composition of functional nicotinic receptors in dopaminergic neurons investigated with knockout mice. J Neurosci 23:7820–7829. https://doi.org/10.1523/JNEUROSCI.23-21-07820.2003

Chao SL, Casida JE (1997) Interaction of imidacloprid metabolites and receptors of differentiating neurons: implications for toxicant sensitivity. Toxicol Appl Pharmacol 354:64–80. https://doi.org/10.1016/j.taap.2017.12.013

Chomczynski P, Sacchi N (2006) The single-step method of RNA isolation by acid guanidinium thiocyanate–phenol–chloroform extraction: twenty-something years on. Nat Protoc 1:581–585. https://doi.org/10.1038/nprot.2006.83

Cimino AM, Boyles AL, Thayer KA, Perry MJ (2017) Effects of neonicotinoid pesticide exposure on human health: a systematic review. Environ Health Perspect 125:155–162. https://doi.org/10.1289/EHP151

Codling G, Al Naggar Y, Giesy JP, Robertson AJ (2016) Concentrations of neonicotinoid insecticides in honey, pollen and honey bees (Apis mellifera L.) in central Saskatchewan, Canada. Chemosphere 144:2321–2328. https://doi.org/10.1016/j.chemosphere.2015.10.135

Craddock HA, Huang D, Turner PC et al (2019) Trends in neonicotinoid pesticide residues in food and water in the United States, 1999–2015. Environ Health 18:7. https://doi.org/10.1186/s12940-018-0441-7

D’Amour KA, Casida JE (1999) Desnitroimidacloprid and nicotine binding site in rat recombinant α4β2 neuronal nicotinic acetylcholine receptor. Pestic Biochem Physiol 64:55–61. https://doi.org/10.1016/pocest.1999.2409

Danker T (2018) ephys2: read, analyze and plot HEKA patchmaster files. R package version 0.12.0. https://github.com/tdanker/ephys2

de Kloet SF, Mansvelder HD, De Vries TJ (2015) Cholinergic modulation of dopamine pathways through nicotinic acetylcholine receptors. Biochem Pharmacol 97:425–438. https://doi.org/10.1016/j.bcp.2015.07.014

Delp J, Gubler S, Cerf M et al (2018a) Stage-specific metabolic features of differentiating neurons: implications for toxicant sensitivity. Toxicol Appl Pharmacol 354:64–80. https://doi.org/10.1016/j.taap.2017.12.013

Delp J, Gubler S, Klima S et al (2018b) A high-throughput approach to identify specific neurotoxicants: developmental toxicants in human neuronal cell function assays. Altex 35:235–253. https://doi.org/10.14573/altex.1712182

Delp J, Funke M, Rudof F et al (2019) Development of a neurotoxicity assay that is tuned to detect mitochondrial toxicants. Arch Toxicol 93:1585–1608. https://doi.org/10.1007/s00204-019-02473-y

Dick RA, Kanne DB, Casida JE (2005) Identification of aldehyde oxidase as the neonicotinoid nitroreductase. Chem Res Toxicol 18:317–323. https://doi.org/10.1021/tr0497371

Donnelly-Boyd HL, Puttfarcken PS, Kuntze-Weimer TA et al (1998) ABT-594 [(R)-5-[(2-Azetidinylmethoxy)-2-Chloropyridine]: a novel, orally effective analgesic acting via neuronal nicotinic iPS-C-derived neurons. PLoS ONE. https://doi.org/10.1371/journal.pone.0125116

Chavez-Noriega LE, Gillespie A, Stauderman KA et al (2000) Characterization of the recombinant human neuronal nicotinic acetylcholine receptors α3β2 and α4β2 stably expressed in HEK293 cells. Neuropharmacology 39:2543–2560. https://doi.org/10.1016/S0028-3908(00)00134-9

Chen M, Tao L, McLean J, Lu C (2014) Quantitative analysis of neonicotinoid insecticide residues in foods: implication for dietary exposures. J Agric Food Chem 62:6082–6090. https://doi.org/10.1021/jf501397m
acetylcholine receptors: I. Vitro Charact J Pharmacol Exp Ther 285:777–786
Douglas MR, Tooker JF (2015) Large-scale deployment of seed treatments has driven rapid increase in use of neonicotinoid insecticides and preemptive pest management in US. Field Crops Environ Sci Technol 49:5088–5097. https://doi.org/10.1012/es056141g

Duzguner V, Erdogan S (2012) Chronic exposure to imidacloprid induces inflammation and oxidative stress in the liver and central nervous system of rats. Pestic Biochem Physiol 104:58–64. https://doi.org/10.1016/j.pestbp.2012.06.011

Dwyer JB, McQuown SC, Leslie FM (2009) The dynamic effects of nicotine on the developing brain. Pharmacol Ther 122:125–139. https://doi.org/10.1016/j.pharmthera.2009.02.003

Eaton JB, Lucero LM, Stratton HR et al (2014) The unique α4(+)/(−)α4 agonist binding site in (α4)3(β2)2 subtype nicotinic acetylcholine receptors permits differential agonist desensitization pharmacology versus the (α4)2(β2)3 subtype. J Pharmacol Exp Ther 348:46–58. https://doi.org/10.1124/jpet.113.208389

Edwards S (2019) lemon: Freshing up your “ggplot2” Plots. R package version 0.4.3. https://CRAN.R-project.org/package=lemon

European Commission (2018) Commission Implementing Regulation (EU) 2018/783 of 29 May 2018 amending Implementing Regulation (EU) No 540/2011 as regards the conditions of approval of the active substance imidacloprid (Text with EEA relevance.) http://data.europa.eu/eli/reg_impl/2018/783/oj

European Commission (2018) Commission Implementing Regulation (EU) 2018/1643 of 5 November 2020 amending Implementing Regulation (EU) No 540/2011 as regards the approval periods of the active substances calcium phosphide, denathonium benzoate, haloxyfop-P, imidacloprid, pencycuron and zetacypermethrin (Text with EEA relevance) http://data.europa.eu/eli/reg_impl/2020/1643/oj

European Food Safety Authority (EFSA) (2016) Peer review of the pesticide risk assessment for the active substance imidacloprid in light of confirmatory data submitted. EFSA J 14:4607. https://doi.org/10.2903/j.efsa.2016.4607

European Food Safety Authority (EFSA), Abdourahime H, Anastasiadou M et al (2019) Review of the existing maximum residue levels for imidacloprid according to article 12 of regulation (EC) No 396/2005. EFSA J 17:e05570. https://doi.org/10.2903/j.efsa.2019.5570

Fenster CP, Rains MF, Noerager B et al (1997) Influence of subunit composition on desensitization of neuronal acetylcholine receptors at low concentrations of nicotine. J Neurosci 17:5747–5759. https://doi.org/10.1523/JNEUROSCI.17-15-05747.1997

Ford KA, Casida JE (2006) Chloropyridyl neonicotinoid insecticides: diverse molecular substrates contribute to facile metabolism in mice. Chem Res Toxicol 19:944–951. https://doi.org/10.1021/tx060069e

Gloor S, Pongs O, Schmalzing G (1995) A vector for the synthesis of cRNAs encoding Myc epitope-tagged proteins in Xenopus laevis oocytes. Gene 160:213–217. https://doi.org/10.1016/0378-1119(95)00226-v

Gopalakrishnan M, Buisson B, Touma E et al (1995) Stable expression and pharmacological properties of the human α7 nicotinic acetylcholine receptor. Eur J Pharmacol Mol Pharmacol 290:237–246. https://doi.org/10.1016/0922-4106(95)00083-6

Gotti C, Carbonnelle E, Moretti M et al (2000) Drugs selective for nicotinic receptor subtypes: a real possibility or a dream? Behav Brain Res 113:183–192. https://doi.org/10.1016/S0166-4328(00)00212-6

Gotti C, Zoli M, Clementi F (2006) Brain nicotinic acetylcholine receptors: native subtypes and their relevance. Trends Pharmacol Sci 27:482–491. https://doi.org/10.1016/j.tips.2006.07.004

Grady S, Marks MJ, Wonnacott S, Collins AC (1992) Characterization of nicotinic receptor-mediated [3H]dopamine release from synaptosomes prepared from mouse striatum. J Neurochem 59:848–856. https://doi.org/10.1111/j.1471-4159.1992.tb08322.x

Grandjean P, Landrigan P (2006) Developmental neurotoxicity of industrial chemicals. Lancet 368:2167–2178. https://doi.org/10.1016/S0140-6736(06)69665-7

Grandjean P, Landrigan PJ (2014) Neurobehavioural effects of developmental toxicity. Lancet Neurol 13:330–338. https://doi.org/10.1016/S1474-4422(13)70728-3

Gray R, Rajan AS, Radcliffe KA et al (1996) Hippocampal synaptic transmission enhanced by low concentrations of nicotine. Nature 383:713–716. https://doi.org/10.1038/383713a0

Gronlien JH, Håkerud M, Ween H et al (2007) Distinct profiles of α7 nAChR positive allosteric modulation revealed by structurally diverse chemotypes. Mol Pharmacol 72:715–724. https://doi.org/10.1124/mol.107.035410

Grothendieck G, Kates L, Petzoldt T (2016) proto: prototype object-based programming. R package version 1.0.0. https://CRAN.R-project.org/package=proto

Grunwald L-M, Stock R, Haag K et al (2019) Comparative characterization of human induced pluripotent stem cells (hiPSC) derived from patients with schizophrenia and autism. Transl Psychiatry 9:179. https://doi.org/10.1038/s41398-019-0517-3

Gustafsson H, Runesson J, Lundqvist J et al (2010) Neurofunctional endpoints assessed in human neuroblastoma SH-SY5Y cells for estimation of acute systemic toxicity. Toxicol Appl Pharmacol 245:191–202. https://doi.org/10.1016/j.taap.2010.02.018

Harpsøe K, Ahring PK, Christensen JK et al (2011) Unraveling the mechanism of binding of choline to the β1 strand as a new structural determinant of neonicotinoid insecticides. Mol Pharmacol 86:736–746. https://doi.org/10.1124/mol.109.054245

Harris G, Hogberg H, Hartung T, Smirnova L (2017) 3D differentiation of LUHMES cell line to study recovery and delayed neurotoxic effects. Curr Protoc Toxicol. https://doi.org/10.1002/cptx.29

Hothorn T, Bretz F, Westfall P (2008) Simultaneous inference in general parametric models. Biom J 50:346–363. https://doi.org/10.1002/bimj.200810425

Hurst RS, Hajós M, Raggenbass M et al (2005) A novel positive allosteric modulator of the α7 neuronal nicotinic acetylcholine receptor. In vitro and in vivo characterization. J Neurosci 25:4396–4405. https://doi.org/10.1523/JNEUROSCI.5269-04.2005

Ihara M, Okajima T, Yamashita A et al (2008) Crystal structures of Lymnaea stagnalis AChBP in complex with neonicotinoid insecticides imidacloprid and clothianidin. Invert Neurosci 8:71–81. https://doi.org/10.1007/s10158-008-0069-3

Ihara M, Okajima T, Yamashita A et al (2014) Studies on an acetylcholine binding protein identify a basic residue in loop G on the β1 strand as a new structural determinant of neonicotinoid actions. Mol Pharmacol 86:736–746. https://doi.org/10.1124/mol.114.094698

Jeschke P, Nauen R, Schindler M, Elbert A (2011) Overview of the status and global strategy for neonicotinoids. J Agric Food Chem 59:2897–2908. https://doi.org/10.1021/jf101303g

Jonsson M, Gurley D, Dabrowski M et al (2006) Distinct pharmacologic properties of neuromuscular blocking agents on human neuronal nicotinic acetylcholine receptors: a possible explanation for the train-of-four fade. Anesthesiology 105:521–533

Karreran C, Klima S, Holzer A-K, Leist M (2020) CaFFEE: a program for evaluating time courses of Ca2+ dependent signal changes of complex cells loaded with fluorescent indicator dyes. Altern Anim Exp ALTEX 37:332–336. https://doi.org/10.14573/altext.2003191
Ooms J (2020) magick: Advanced graphics and image-processing in R. R package version 2.3. https://CRAN.R-project.org/package=magick

Palma E, Bertrand S, Binzoni T, Bertrand D (1996) Neuronal nicotinic alpha 7 receptor expressed in Xenopus oocytes presents five putative binding sites for methyllycaconitine. J Physiol 491:151–161. https://doi.org/10.1113/jphysiol.1996.sp021203

Papke RL, Dwoskin LP, Crooks PA et al (2008) Extending the analysis of nicotinic receptor antagonists with the study of α6 nicotinic receptor subunit chimeras. Neuropharmacology 54:1189–1200. https://doi.org/10.1016/j.neuropharm.2008.03.010

Papke RL, Kem WR, Soti F et al (2009) Activation and desensitization of nicotinic α7-type acetylcholine receptors by benzylidene anabaseines and nicotine. J Pharmacol Exp Ther 329:791–807. https://doi.org/10.1124/jpet.108.150151

Papke RL, Trocmé-Thibierge C, Guendisch D et al (2011) Electro-physiological perspectives on the therapeutic use of nicotinic acetylcholine receptor partial agonists. J Pharmacol Exp Ther 337:367–379. https://doi.org/10.1124/jpet.110.177485

Paradiso KG, Steinbach JH (2003) Nicotine is highly effective at producing desensitization of Rat α4β2 neuronal nicotinic receptors. J Physiol 553:857–871. https://doi.org/10.1113/jphysiol.2003. 053447

Pryde DC, Dalvie D, Hu Q et al (2010) Aldehyde oxidase: an enzyme of emerging importance in drug discovery. J Med Chem 53:8441–8460. https://doi.org/10.1021/jm100888d

Puchacz E, Buisson B, Bertrand D, Lukas RJ (1994) Functional expression of nicotinic acetylcholine receptors containing rat α7 subunits in human SH-SY5Y neuroblastoma cells. FEBs Lett 354:155–159. https://doi.org/10.1016/0014-5793(94)01108-7

Quick MW, Lester RAJ (2002) Desensitization of neuronal nicotinic receptors. J Neurobiol 53:457–478. https://doi.org/10.1002/neu. 10109

Quik M, Kulak JM (2002) Nicotine and nicotinic receptors; relevance to parkinson’s disease. Neurotoxicology 23:581–594. https://doi.org/10.1016/S0161-813X(02)00036-0

Quik M, Wonnacott S (2011) α6β2* and α4β2* Nicotinic acetylcholine receptors as drug targets for parkinson’s disease. Pharmacol Rev 63:938–966. https://doi.org/10.1124/pr.110.003269

R Core Team (2020) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https://www.R-project.org

Rapier C, Lunt GG, Wonnacott S (1988) Stereoselective nicotine-induced release of dopamine from striatal synaptosomes: concentration dependence and repetitive stimulation. J Neurochem 50:1123–1130. https://doi.org/10.1111/j.1471-4479. 1988.tb10582.x

Ring A, Strom BO, Turner SR et al (2015) Bispyridylium compounds inhibit both muscle and neuronal nicotinic acetylcholine receptors in human cell lines. PLoS ONE 10:e0135811. https://doi.org/10.1371/journal.pone.0135811

Ritz C, Baty F, Streibig JC, Gerhard D (2015) Dose-response analysis using r. PLoS ONE 10:e0146021. https://doi.org/10.1371/journal.pone.0146021

Rollemo H, Hurst RS (2018) The contribution of agonist and antagonist activities of α4β2* nAChR ligands to smoking cessation efficacy: a quantitative analysis of literature data. Psychopharmacology 235:2479–2505. https://doi.org/10.1007/s00213-018-4921-9

Rollemo H, Shrikhande A, Ward KM et al (2010) Pre-clinical properties of the α4β2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianiscline to translate to clinical efficacy for nicotine dependence. Br J Pharmacol 160:334–345. https://doi.org/10.1111/j.1476-5381.2010.00682.x

Romoli B, Lozada AF, Sandoval IM et al (2019) Neonatal nicotine exposure primes midbrain neurons to a dopaminergic phenotype and increases adult drug consumption. Biol Psychiatry 86:344–355. https://doi.org/10.1016/j.biopsych.2019.04.019

Rovida C, Barton-Maclaren T, Benfenati E et al (2020) Internationalization of read-across as a validated new approach method (NAM) for regulatory toxicology. ALTEX Altern Anim Exp 37:579–606. https://doi.org/10.14373/altex.1912181

Schildknecht S, Karremann S, Pöltl D et al (2015) Generation of genetically-modified human differentiated cells for toxicological tests and the study of neurodegenerative diseases. ALTEX Altern Anim Exp 30:427–444. https://doi.org/10.14373/altex.2013.4. 427

Schildknecht S, Pape R, Meiser J et al (2015) Preferential extracellular generation of the active parkinsonian toxin MPP+ by transporter-independent export of the intermediate MPPD+. Antioxid Redox Signal 23:1001–1016. https://doi.org/10.1089/ars.2015.6297

Scholz D, Pöltl D, Genewsky A et al (2011) Rapid, complete and large-scale generation of post-mitotic neurons from the human LUHMES cell line. J Neurochem 119:957–971. https://doi.org/10.1111/j.1471-4519.2011.07255.x

Schulz-Jander DA, Casida JE (2002) Imidacloprid insecticide metabolism: human cytochrome P450 isoforms differ in selectivity for imidazolidine oxidation versus nitroimine reduction. Toxicol Lett 132:65–70. https://doi.org/10.1016/S0378-4274(02)00068-1

Schulz-Jander DA, Leimkuhler WM, Casida JE (2002) Neonicotinoid insecticides; reduction and cleavage of imidacloprid nitroimine substituent by liver microsomal and cytosolic enzymes. Chem Res Toxicol 15:1158–1165. https://doi.org/10.1021/tr0203060

Simon-Delso N, Amaral-Rogers V, Belzunces LP et al (2015) Systemic insecticides (neonicotinoids and fipronil): trends, uses, mode of action and metabolites. Environ Sci Pollut Res 22:5–34. https://doi.org/10.1007/s11356-014-3470-y

Sireno O, Parham F, Dea S et al (2019) Functional and mechanistic neurotoxicity profiling using human iPSC-derived neural 3D cultures. Toxicol Sci 167:58–76. https://doi.org/10.1093/ toxicsci/kfy218

Sliker W Jr, Xu ZA, Levin ED, Slotkin TA (2005) Mode of action: disruption of brain cell replication, second messenger, and neurotransmitter systems during development leading to cognitive dysfunction—developmental neurotoxicity of nicotine. Crit Rev Toxicol 35:703–715. https://doi.org/10.1080/10408404.2010.107421

Slotkin TA, Tate CA, Cousins MM, Seidler FJ (2006) Prenatal nicotine exposure alters the responses to subsequent nicotine administration and withdrawal in adolescence: serotonin receptors and cell signaling. Neuropsychopharmacology 31:2462–2475. https://doi.org/10.1038/sj.npp.1300998

Slotkin TA, Skavicus S, Card J et al (2016) Diverse neurotoxins target the differentiation of embryonic neural stem cells into neuronal and glial phenotypes. Toxicology 372:42–51. https://doi.org/10.1016/j.tox.2016.10.015

Smirnova L, Harris G, Delp J et al (2016) A LUHMES 3D dopaminergic neuronal model for neurotoxicity testing allowing long-term exposure and cellular resilience analysis. Arch Toxicol 90:2725–2743. https://doi.org/10.1007/s00204-015-1637-z

Sparks TC, Nauen R (2015) IRAC: mode of action classification and insecticide resistance management. Pestic Biochem Physiol 121:122–128. https://doi.org/10.1016/j.pestbp.2014.11.014

Sparks TC, Crosssthwaite AJ, Nauen R et al (2020) Insecticides, biology and nematocides; Updates to IRAC’s mode of action classification—a tool for resistance management. Pestic Biochem Physiol 167:104587. https://doi.org/10.1016/j.pestbp.2020.104587

Swenson TL, Casida JE (2013) Aldehyde oxidase importance in vivo in xenobiotic metabolism; imidacloprid nitroreduction in mice. Toxicol Sci 133:22–28. https://doi.org/10.1093/toxsci/kft066
